Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving cisplatin and irinotecan together with
bevacizumab works in treating patients with extensive-stage small cell lung cancer. Drugs
used in chemotherapy, such as cisplatin and irinotecan, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some
block the ability of tumor cells to grow and spread. Others find tumor cells and help kill
them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of small
cell lung cancer by blocking blood flow to the tumor. Giving cisplatin and irinotecan
together with bevacizumab may kill more tumor cells.